Preprint Review Version 3 Preserved in Portico This version is not peer-reviewed

Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents

Version 1 : Received: 12 October 2019 / Approved: 13 October 2019 / Online: 13 October 2019 (15:22:27 CEST)
Version 2 : Received: 7 November 2019 / Approved: 7 November 2019 / Online: 7 November 2019 (14:59:43 CET)
Version 3 : Received: 26 December 2019 / Approved: 27 December 2019 / Online: 27 December 2019 (03:35:32 CET)
Version 4 : Received: 27 January 2020 / Approved: 27 January 2020 / Online: 27 January 2020 (02:09:09 CET)
Version 5 : Received: 7 February 2020 / Approved: 10 February 2020 / Online: 10 February 2020 (09:55:44 CET)
Version 6 : Received: 12 February 2020 / Approved: 14 February 2020 / Online: 14 February 2020 (02:27:24 CET)

How to cite: Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; Tenson, T.; Kantele, A.; Kainov, D.E. Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. Preprints 2019, 2019100144 (doi: 10.20944/preprints201910.0144.v3). Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; Tenson, T.; Kantele, A.; Kainov, D.E. Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. Preprints 2019, 2019100144 (doi: 10.20944/preprints201910.0144.v3).

Abstract

Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs) could provide additional protection of general population from emerging and re-emerging viral diseases reinforcing the arsenal of available antiviral options. Here, we reviewed development process of BSAAs and summarized the information on 119 safe-in-man agents in freely accessible database (https://drugvirus.info/). The number of BSAAs will be increased, their developmental status will be updated, spectrum of their indications will be expanded, as well as BSAA combinations will be approved pending the results of further pre-clinical and clinical studies.

Subject Areas

virus; antiviral drug; drug discovery; drug development; broad-spectrum antivirals

Comments (1)

Comment 1
Received: 27 December 2019
Commenter: Denis Kainov
Commenter's Conflict of Interests: Author
Comment: We introduced changes in the preprint following referees' comments.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.